Transforming HIV Care Through Innovation
The story of HIV treatment is one of remarkable scientific progress. What was once a devastating diagnosis with limited options has, over four decades, been transformed into a manageable chronic condition for millions of people around the world. Antiretroviral therapy (ART) has been the cornerstone of this transformation, suppressing viral loads, restoring immune function, and enabling people living with HIV to lead long, healthy lives.
Yet despite these advances, challenges remain. Daily oral medication regimens can be burdensome, contributing to treatment fatigue, adherence difficulties, and the persistent stigma that many people living with HIV continue to face. These challenges have driven a new wave of innovation in HIV care: long-acting therapies that replace daily pills with periodic injections, offering a fundamentally different treatment experience.
The Science of Long-Acting Antiretrovirals
Long-acting injectable therapies represent a paradigm shift in HIV treatment. Through ViiV Healthcare β a specialist HIV company majority-owned by GSK β researchers have developed formulations that maintain therapeutic drug concentrations in the body for weeks or months after a single injection. The technology relies on nano-suspension formulations that create a drug depot at the injection site, releasing medication slowly and steadily over an extended period.
This approach offers several compelling advantages:
- Reduced pill burden: Patients transition from daily oral regimens to injections every one or two months, dramatically simplifying their treatment routine.
- Improved adherence: By removing the need for daily medication, long-acting therapies address one of the most common reasons for treatment failure β inconsistent adherence.
- Reduced stigma: For many people, daily pills serve as a constant reminder of their HIV status. Long-acting injections offer a more discreet treatment option that can improve psychological well-being and quality of life.
- Prevention potential: Long-acting antiretrovirals are also being developed for pre-exposure prophylaxis (PrEP), offering a new tool for preventing HIV transmission in high-risk populations.
Clinical Evidence and Real-World Impact
Clinical trials have demonstrated that long-acting injectable regimens are non-inferior to daily oral therapy in maintaining viral suppression, with high levels of patient satisfaction and preference. In real-world settings, studies have shown that patients who switch to long-acting injectables report significant improvements in treatment satisfaction, with many describing a sense of freedom and normalcy that daily pills could not provide.
Healthcare providers have also noted practical benefits, including more structured patient engagement through regular clinic visits for injections, which can facilitate holistic care that addresses not only HIV but also comorbidities, mental health, and social support needs.
Advancing Prevention: Long-Acting PrEP
Beyond treatment, long-acting antiretrovirals are opening new frontiers in HIV prevention. Pre-exposure prophylaxis (PrEP) β the use of antiretroviral drugs by HIV-negative individuals to prevent infection β has proven highly effective when taken consistently. However, daily oral PrEP faces adherence challenges similar to those in treatment, particularly among young people and marginalised communities who bear a disproportionate burden of new infections.
Long-acting injectable PrEP has the potential to transform prevention by providing sustained protection with periodic injections, removing the need for daily adherence. Clinical studies have shown superior efficacy compared to daily oral PrEP in certain populations, and regulatory approvals are expanding access globally.
ViiV Healthcare and GSKβs HIV Commitment
ViiV Healthcareβs dedication to ending the HIV epidemic is reflected in its comprehensive approach to research, access, and community engagement. The company invests heavily in innovation across the HIV treatment and prevention landscape, with a pipeline that includes next-generation long-acting agents, broadly neutralising antibodies, and investigational cure strategies.
Equally important is ViiVβs commitment to global access. Through partnerships with generic manufacturers, international health organisations, and community groups, ViiV works to ensure that innovative HIV therapies reach the people who need them most, including in sub-Saharan Africa, where two-thirds of all people living with HIV reside.
The Road Ahead
Long-acting therapies represent a pivotal step towards a future where HIV treatment and prevention are simpler, more effective, and more accessible than ever before. As research continues to push boundaries β exploring even longer dosing intervals, new delivery mechanisms, and combination approaches β the vision of ending the HIV epidemic is moving closer to reality. Through ViiV Healthcare and its broader commitment to global health, GSK is proud to be at the forefront of this transformation.